Reviewing the Recommendations for Lupus in Children

Current Rheumatology Reports

Volumn 17, Issue 3, 2015, Pages

  Arıcı, Zehra Serap ^a   Batu, Ezgi Deniz ^a   Ozen, Seza ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Child; Lupus nephritis; Management; Pediatric; SLE; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BELIMUMAB; CALCINEURIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; EPRATUZUMAB; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; RETINOID; RITUXIMAB; STEROID; SUNSCREEN; TACROLIMUS; THALIDOMIDE; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ANTICOAGULANT THERAPY; ARTHRITIS; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; END STAGE RENAL DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ARTHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MACROPHAGE ACTIVATION SYNDROME; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; PLASMAPHERESIS; REVIEW; SKIN PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VEIN THROMBOSIS; CHILD; DISEASE MANAGEMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINE; QUALITY OF LIFE;

CHILD; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 84924787481     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0489-5     Document Type: Review

References (152)

1. Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25(5):616–22. doi:10.1097/BOR.0b013e328363e868.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235. doi:10.1161/CIRCULATIONAHA.105.167586.
3. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82. doi:10.1136/annrheumdis-2012-201940. This is the EULAR/ERA-EDTA recommendations for lupus nephritis management.
4. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. doi:10.1002/acr.21664. This is the EULAR/ERA-EDTA recommendations for lupus nephritis management.
5. Pons-Estel GJ, Alarcon GS, McGwin Jr G, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–9. doi:10.1002/art.24538.
6. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–5.
7. Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G, et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(9):1416–23. doi:10.1002/acr.21998.
8. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22. doi:10.1016/j.ophtha.2010.11.017.
9. Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol. 2012;4(2):146–51. doi:10.4161/derm.20443.
10. Vachvanichsanong P, McNeil E. Pediatric lupus nephritis: more options, more chances? Lupus. 2013;22(6):545–53. doi:10.1177/0961203313485490.
11. Sinha R, Raut S. Pediatric lupus nephritis: Management update. World J Nephrol. 2014;3(2):16–23. doi:10.5527/wjn.v3.i2.16.
12. Heijstek MW, de Bruin LM O, Bijl M, Borrow R, van der Klis F, Kone-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–12. doi:10.1136/ard.2011.150193.
13. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–22. doi:10.1136/ard.2010.137216.
14. Machado APBDM, Vandresen N, Skare TL. Mucocutaneous involvement in systemic lupus erythematosus and its association with autoantibodies. An Bras Dermatol. 2008;83:323–8.
15. Zecevic RD, Vojvodic D, Ristic B, Pavlovic MD, Stefanovic D, Karadaglic D. Skin lesions—an indicator of disease activity in systemic lupus erythematosus? Lupus. 2001;10(5):364–7.
16. Chiewchengchol D, Murphy R, Morgan T, Edwards SW, Leone V, Friswell M, et al. Mucocutaneous manifestations in a UK national cohort of juvenile-onset systemic lupus erythematosus patients. Rheumatology (Oxford). 2014;53(8):1504–12. doi:10.1093/rheumatology/keu137.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y.
18. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011;65(6):e195–213. doi:10.1016/j.jaad.2010.06.017.
19. Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum. 2004;50(9):3045–6. doi:10.1002/art.20426.
20. Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011;64(1):37–48. doi:10.1016/j.jaad.2009.12.053.
21. Patsinakidis N, Wenzel J, Landmann A, Koch R, Gerss J, Luger TA, et al. Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. Exp Dermatol. 2012;21(12):958–61. doi:10.1111/exd.12035.
22. Ting WW, Sontheimer RD. Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations. Lupus. 2001;10(3):171–84.
23. Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol. 2003;13(5):455–61.
24. Moura Filho JP, Peixoto RL, Martins LG, Melo SD, Carvalho LL, Pereira AK, et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol. 2014;89(1):118–25. doi:10.1590/abd1806-4841.20142146.
25. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: Diagnostics and therapeutics. Best Pract Res Clin Rheumatol. 2004;18(3):429–62. doi:10.1016/j.berh.2004.03.003.
26. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26(6):1275–9.
27. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59(12):1796–804. doi:10.1002/art.24068.
28. Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15(1):62–8. doi:10.1111/j.1756-185X.2011.01665.x.
29. Gronhagen CM, Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014;5(1):7–13. doi:10.4103/2229-5178.126020.
30. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med. 1990;74(275):319–30.
31. Reilly PA, Evison G, McHugh NJ, Maddison PJ. Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol. 1990;17(6):777–84.
32. Silverman EEA et al. Systemic lupus eryhtematosus. In: Cassidy JT PR, Laxer RM, editors. Textbook of pediatric rheumatology. Philadelphia: Saunders Elseiver; 2011. p. 315–42.
33. Ball EM, Bell AL. Lupus arthritis—do we have a clinically useful classification? Rheumatology (Oxford). 2012;51(5):771–9. doi:10.1093/rheumatology/ker381.
34. Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol. 2009;23(4):495–506. doi:10.1016/j.berh.2009.04.003.
35. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52. doi:10.1002/art.27221.
36. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48(11):1451–4. doi:10.1093/rheumatology/kep270.
37. Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.
38. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–6. doi:10.1016/j.jpeds.2007.09.019.
39. Sibbitt Jr WL, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29(7):1536–42.
40. Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus. 2006;15(10):651–7.
41. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608. doi:10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F. This is the ACR case definitions for neuropsychiatric lupus syndromes which form the basis for neuropsychiatric lupus management.
42. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16(8):564–71. doi:10.1177/0961203307078971.
43. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–82. doi:10.1136/ard.2010.130476. This is the only recommendation set specific for management of lupus with neuropsychiatric involvement based on systematic literature review.
44. Demirkaya E, Bilginer Y, Aktay-Ayaz N, Yalnizoglu D, Karli-Oguz K, Isikhan V, et al. Neuropsychiatric involvement in juvenile systemic lupus erythematosus. Turk J Pediatr. 2008;50(2):126–31.
45. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127(Pt 5):1200–9. doi:10.1093/brain/awh146.
46. Zuniga Zambrano YC, Guevara Ramos JD, Penagos Vargas NE, Benitez Ramirez DC, Ramirez Rodriguez SM, Vargas Nino AC, et al. Risk factors for neuropsychiatric manifestations in children with systemic lupus erythematosus: Case–control study. Pediatr Neurol. 2014;51(3):403–9. doi:10.1016/j.pediatrneurol.2014.03.027.
47. Joseph FG, Scolding NJ. Neurolupus. Pract Neurol. 2010;10(1):4–15. doi:10.1136/jnnp.2009.200071.
48. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–5. doi:10.1136/ard.2004.025528. This is the only randomized controlled trial on neuropsychiatric lupus treatment.
49. Fernandes Moca Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2013;2:CD002265. doi:10.1002/14651858.CD002265.pub3.
50. Bartolucci P, Brechignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16(10):817–22. doi:10.1177/0961203307081840.
51. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003;7(2):173–82.
52. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin—Clinical and serologic response. Lupus. 1999;8(9):705–12.
53. Milstone AM, Meyers K, Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol. 2005;24(4):394–7. doi:10.1007/s10067-004-1046-9.
54. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44(2):175–85. doi:10.1016/j.semarthrit.2014.04.002.
55. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5. doi:10.1136/ard.2006.057885.
56. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8. doi:10.1056/NEJMoa035241.
57. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848–53. doi:10.1111/j.1538-7836.2005.01340.x.
58. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050–7. doi:10.1001/jama.295.9.1050.
59. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487–95. doi:10.1002/art.23109.
60. Tektonidou MG, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93(8):523–30.
61. Gokce M, Bilginer Y, Besbas N, Ozaltin F, Cetin M, Gumruk F, et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012;21(8):878–84. doi:10.1177/0961203312443721.
62. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):412–5. doi:10.1136/ard.2008.094813.
63. Voulgarelis M, Kokori SI, Ioannidis JP, Tzioufas AG, Kyriaki D, Moutsopoulos HM. Anaemia in systemic lupus erythematosus: Aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000;59(3):217–22.
64. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006;65(2):144–8. doi:10.1136/ard.2005.041673.
65. Habib GS, Saliba WR, Froom P. Pure red cell aplasia and lupus. Semin Arthritis Rheum. 2002;31(4):279–83.
66. Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus—Old and new. Autoimmun Rev. 2013;12(7):784–91. doi:10.1016/j.autrev.2013.02.001.
67. Levine AB, Erkan D. Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep. 2011;13(4):291–9. doi:10.1007/s11926-011-0179-5.
68. Mondal R, Nandi M, Ganguli S, Ghosh A, Hazra A. Childhood lupus: experience from Eastern India. Indian J Pediatr. 2010;77(8):889–91. doi:10.1007/s12098-010-0126-x.
69. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol. 1997;24(11):2153–7.
70. Vasiliu IM, Petri MA, Baer AN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol. 2006;33(9):1878–80.
71. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford). 2010;49(12):2243–54. doi:10.1093/rheumatology/keq269.
72. Schmugge M, Revel-Vilk S, Hiraki L, Rand ML, Blanchette VS, Silverman ED. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr. 2003;143(5):666–9. doi:10.1067/S0022-3476(03)00389-5.
73. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15(4):223–31.
74. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117(3):712–5.
75. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus. 2005;14(10):856–8.
76. Quartuccio L, Sacco S, Franzolini N, Perin A, Ferraccioli G, De Vita S. Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus. 2006;15(2):76–9.
77. Thabet AF, Faisal M. Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective. Indian J Hematol Blood Transfus. 2014;30(4):313–8. doi:10.1007/s12288-013-0290-z.
78. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003;12(8):630–2.
79. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg. 2004;240(2):286–92.
80. Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin Arthritis Rheum. 2011;40(4):298–306. doi:10.1016/j.semarthrit.2010.03.005.
81. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12(2):163–8.
82. Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum. 1990;33(8):1233–9.
83. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147(4):521–7. doi:10.1016/j.jpeds.2005.04.032.
84. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S9–56. doi:10.1016/j.tmrv.2007.01.001.
85. Kamat AV, D’Cruz DP, Hunt BJ. Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica. 2006;91(12):1674–80.
86. Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523. doi:10.1016/j.rdc.2007.07.001.
87. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382–91. doi:10.1002/art.22663.
88. Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13(3):281–91. doi:10.1016/j.autrev.2013.10.014. This is a recent metanalysis on efficacy of aspirin for primary prophylaxis of thrombosis in patients with antiphospholipid antibodies.
89. Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014;53(2):275–84. doi:10.1093/rheumatology/ket313.
90. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18. doi:10.1177/0961203310395803. This is the most recent evidence-based recommendations for management of patients with antiphospholipid antibodies.
91. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8. doi:10.1002/art.27289.
92. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–83.
93. Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 2008;47(11):1686–91. doi:10.1093/rheumatology/ken342.
94. Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388–99. doi:10.1002/art.24883.
95. Bennett TD, Fluchel M, Hersh AO, Hayward KN, Hersh AL, Brogan TV, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(12):4135–42. doi:10.1002/art.34661.
96. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14(5):548–52.
97. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257–68. doi:10.1016/j.semarthrit.2008.10.007.
98. Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis. 1998;57(8):456–9.
99. Perfumo F, Martini A. Lupus nephritis in children. Lupus. 2005;14(1):83–8.
100. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–50.
101. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62. doi:10.1002/art.23204.
102. Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol. 2007;22(1):77–83. doi:10.1007/s00467-006-0296-y.
103. Sorof JM, Perez MD, Brewer ED, Hawkins EP, Warren RW. Increasing incidence of childhood class V lupus nephritis. J Rheumatol. 1998;25(7):1413–8.
104. Houssiau FA, Lauwerys BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol. 2013;27(3):319–28. doi:10.1016/j.berh.2013.07.004.
105. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257–63. doi:10.1177/0961203308100481.
106. Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010;99(7):967–74. doi:10.1111/j.1651-2227.2010.01771.x.
107. Group KDIGOKGW. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(Suppl.):139–274. This is the KDIGO guideline including recommendations for management of lupus nephritis.
108. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–67. doi:10.1136/annrheumdis-2013-205139. This is the recent treat-to-target recommendations for SLE from an international task force.
109. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006;119(4):355 e25–33. doi:10.1016/j.amjmed.2005.08.045.
110. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–4. doi:10.1136/ard.2008.102533.
111. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr. 2000;136(2):243–7.
112. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr. 1989;114(6):1055–60. This is the largest lupus nephritis therapy trial.
113. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12. doi:10.1681/ASN.2008101028.
114. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40. doi:10.1093/rheumatology/kep346.
115. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78. doi:10.3899/jrheum.100130.
116. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152–60. doi:10.1038/ki.2009.412.
117. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74–87. doi:10.1053/j.ajkd.2012.08.041.
118. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2014;41(10):1998–2007. doi:10.3899/jrheum.140050.
119. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized, controlled trial. Ann Intern Med. 2014. doi:10.7326/M14-1030. This study is the largest series of MMF use in children with SLE.
120. Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child. 2010;95(12):1059–61. doi:10.1136/adc.2009.178608.
121. Austin 3rd HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20(4):901–11. doi:10.1681/ASN.2008060665.
122. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis Offic J Nat Kidney Found. 2011;57(2):235–44. doi:10.1053/j.ajkd.2010.08.036.
123. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res. 2012;64(3):375–83. doi:10.1002/acr.21558.
124. Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus. 2011;20(13):1442–9. doi:10.1177/0961203311416034.
125. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheum. 2014;66(2):379–89. doi:10.1002/art.38260.
126. Group AT. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheum. 2014;66:3096–104. doi:10.1002/art.38790.
127. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015;11(1):46–61. doi:10.1038/nrneph.2014.215. This is the most recent review evaluating the literature on lupus nephritis management in detail.
128. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–9. doi:10.1136/ard.2010.131995.
129. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95. doi:10.1056/NEJMoa1014460.
130. Feng L, Deng J, Huo DM, Wu QY, Liao YH. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013;18(2):104–10. doi:10.1111/nep.12006. This is a recent matanalysis comparing MMF and AZA in lupus nephritis maintenance treatment.
131. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357–64. doi:10.1016/j.autrev.2011.10.009.
132. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2011;40(3):159–69. doi:10.1007/s12016-010-8205-3.
133. Marks SD, Tullus K. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date. Paediatr Drugs. 2007;9(6):371–8.
134. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. doi:10.1002/art.27233.
135. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26. doi:10.1002/art.34359.
136. Ale’ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int. 2014;34(4):529–33. doi:10.1007/s00296-013-2896-8.
137. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3168–74. doi:10.1002/art.21351.
138. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23(3):413–9. doi:10.1007/s00467-007-0694-9.
139. Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3. doi:10.1186/1546-0096-12-3.
140. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes—Mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010;25(12):3939–48. doi:10.1093/ndt/gfq322.
141. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010;19(8):974–80. doi:10.1177/0961203310366573.
142. Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulations in adult renal transplantation—update on efficacy and tolerability. Ther Clin Risk Manag. 2009;5(4):341–51.
143. Harada T, Ozono Y, Miyazaki M, Sasaki O, Miyazaki K, Abe K, et al. Plasmapheresis in the treatment of rapidly progressive glomerulonephritis. Ther Apher. 1997;1(4):366–9.
144. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8. doi:10.1136/annrheumdis-2011-200831.
145. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–79. doi:10.1002/art.38037.
146. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74. doi:10.1186/ar1942.
147. Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol. 2009;5(4):391–403. doi:10.1586/eci.09.29.
148. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with systemic lupus erythematosus. Transpl Int. 2003;16(6):411–8. doi:10.1007/s00147-003-0563-9.
149. Moroni G, Tantardini F, Gallelli B, Quaglini S, Banfi G, Poli F, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis. 2005;45(5):903–11.
150. Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int. 2000;57(5):2136–43. doi:10.1046/j.1523-1755.2000.00065.x.
151. Vaidya S, Sellers R, Kimball P, Shanahan T, Gitomer J, Gugliuzza K, et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation. 2000;69(7):1348–52.
152. Vaidya S, Wang CC, Gugliuzza C, Fish JC. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant. 1998;12(5):439–44.